The	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
is	O
downregulated	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

PU.1	B-protein
is	O
a	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
belonging	O
to	O
the	O
Ets-family	B-protein
.	O

It	O
is	O
identical	O
to	O
the	O
Spi-1	B-DNA
oncogene	I-DNA
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus-forming	O
virus-induced	O
murine	O
erythroleukemias	O
.	O

PU.1	B-protein
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	B-cell_type
hematopoietic	I-cell_type
lineages	I-cell_type
,	O
but	O
its	O
expression	O
in	O
mature	B-cell_type
cells	I-cell_type
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B-cell-and	B-cell_type
monocyte/macrophage-differentiation	I-cell_type
lineage	I-cell_type
.	O

It	O
binds	O
the	O
so-called	O
Pu	B-DNA
box	I-DNA
,	O
an	O
important	O
tissue-specific	B-DNA
regulatory	I-DNA
DNA	I-DNA
element	I-DNA
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	B-cell_type
lineages	I-cell_type
.	O

We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU.1	B-protein
during	O
human	O
B-cell	O
development	O
using	O
a	O
panel	O
of	O
B-cell	B-cell_line
lines	I-cell_line
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	B-cell_line
precursors	I-cell_line
to	O
differentiated	B-cell_line
plasma	I-cell_line
cells	I-cell_line
.	O

PU.1	B-RNA
mRNA	I-RNA
expression	O
and	O
PU.1	B-protein
DNA	O
binding	O
activity	O
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
were	O
evident	O
in	O
cell	B-cell_line
lines	I-cell_line
representing	O
pro-B	B-cell_line
,	I-cell_line
pre-B	I-cell_line
,	I-cell_line
and	I-cell_line
mature	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

We	O
could	O
also	O
show	O
Pu	B-DNA
box	I-DNA
-dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O

In	O
contrast	O
,	O
in	O
a	O
number	O
of	O
multiple	B-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
representing	O
differentiated	B-cell_type
,	I-cell_type
plasma	I-cell_type
cell-like	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
PU.1	B-protein
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	B-DNA
box	I-DNA
-dependent	O
transactivation	O
were	O
absent	O
or	O
detectable	O
at	O
a	O
very	O
low	O
level	O
.	O

In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O

The	O
findings	O
in	O
the	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
represent	O
the	O
first	O
examples	O
of	O
B	B-cell_type
cells	I-cell_type
with	O
downregulated	O
PU.1	B-protein
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	B-protein
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU.1	B-protein
expression	O
and	O
activity	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
represents	O
a	O
malignancy-associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O
regulation	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	NULL
Hematopoietic	NULL
Transcription	NULL
Factor	NULL
PU.1	NULL
Is	NULL
Downregulated	NULL
in	NULL
Human	NULL
Multiple	NULL
Myeloma	NULL
Cell	NULL
Lines	NULL
By	NULL
Monica	NULL
Pettersson	NULL
,	NULL
Christer	NULL
Sundstrom	NULL
,	NULL
Kenneth	NULL
Nilsson	NULL
,	NULL
and	NULL
Lars-Gunnar	NULL
Larsson	NULL
PU.1	NULL
is	NULL
a	NULL
hematopoietic	NULL
transcription	NULL
factor	NULL
belonging	NULL
to	NULL
the	NULL
Ets-family	NULL
.	NULL

It	NULL
is	NULL
identical	NULL
to	NULL
the	NULL
Spi-1	NULL
oncogene	NULL
,	NULL
which	NULL
is	NULL
implicated	NULL
in	NULL
spleen	NULL
focus-forming	NULL
virus-induced	NULL
murine	NULL
erythroleukemias	NULL
.	NULL

PU.1	NULL
seems	NULL
to	NULL
be	NULL
required	NULL
for	NULL
early	NULL
development	NULL
of	NULL
multiple	NULL
hematopoietic	NULL
lineages	NULL
,	NULL
but	NULL
its	NULL
expression	NULL
in	NULL
mature	NULL
cells	NULL
is	NULL
preferentially	NULL
observed	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
B-cell-	NULL
and	NULL
monocyte/macrophage-differentiation	NULL
lineage	NULL
.	NULL

It	NULL
binds	NULL
the	NULL
so-called	NULL
Pu	NULL
box	NULL
,	NULL
an	NULL
important	NULL
tissue-specific	NULL
regulatory	NULL
DNA	NULL
element	NULL
present	NULL
in	NULL
a	NULL
number	NULL
of	NULL
genes	NULL
expressed	NULL
in	NULL
these	NULL
cell	NULL
lineages	NULL
.	NULL

We	NULL
have	NULL
analyzed	NULL
the	NULL
expression	NULL
and	NULL
activity	NULL
of	NULL
PU.1	NULL
during	NULL
human	NULL
B-cell	NULL
development	NULL
using	NULL
a	NULL
panel	NULL
of	NULL
B-cell	NULL
lines	NULL
representing	NULL
different	NULL
stages	NULL
of	NULL
matura-tion	NULL
,	NULL
from	NULL
early	NULL
precursors	NULL
to	NULL
differentiated	NULL
plasma	NULL
cells	NULL
.	NULL

PU.1	NULL
mRNA	NULL
expression	NULL
and	NULL
PU.1	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
evident	NULL
in	NULL
cell	NULL
lines	NULL
representing	NULL
pro-B	NULL
,	NULL
pre-B	NULL
,	NULL
and	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL

We	NULL
could	NULL
also	NULL
show	NULL
Pu	NULL
box-dependent	NULL
transactivation	NULL
of	NULL
a	NULL
reporter	NULL
gene	NULL
N	NULL
IMPORTANT	NULL
AREA	NULL
of	NULL
research	NULL
on	NULL
cellular	NULL
differentiation	NULL
is	NULL
the	NULL
identification	NULL
of	NULL
transcription	NULL
factors	NULL
regulating	NULL
cell	NULL
lineage-	NULL
and	NULL
differentiation	NULL
stage-specific	NULL
gene	NULL
expression	NULL
.	NULL

Examples	NULL
of	NULL
such	NULL
factors	NULL
in	NULL
the	NULL
hematopoietic	NULL
system	NULL
are	NULL
the	NULL
Oct-2	NULL
``	NULL
and	NULL
GATA	NULL
family	NULL
proteins	NULL
.	NULL
``	NULL

Another	NULL
transcription	NULL
factor	NULL
specific	NULL
for	NULL
hematopoietic	NULL
cells	NULL
is	NULL
PU.1	NULL
,	NULL
originally	NULL
described	NULL
as	NULL
a	NULL
lymphoid-	NULL
and	NULL
macrophage-specific	NULL
factor	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
by	NULL
gene	NULL
targeting	NULL
,	NULL
PU.1	NULL
was	NULL
recently	NULL
shown	NULL
to	NULL
be	NULL
required	NULL
for	NULL
the	NULL
development	NULL
of	NULL
multiple	NULL
hematopoietic	NULL
lineages	NULL
.	NULL
``	NULL

PU.1	NULL
belongs	NULL
to	NULL
the	NULL
ets	NULL
proto-oncogene	NULL
family	NULL
(	NULL
including	NULL
Ets1	NULL
,	NULL
Ets2	NULL
,	NULL
Erg	NULL
,	NULL
Elf1	NULL
,	NULL
GABPa	NULL
,	NULL
PEA3	NULL
,	NULL
Fli-1	NULL
,	NULL
E74A	NULL
,	NULL
Elk1	NULL
,	NULL
and	NULL
SAP1	NULL
)	NULL
characterized	NULL
by	NULL
the	NULL
well-conserved	NULL
ETS	NULL
domain	NULL
that	NULL
mediates	NULL
specific	NULL
DNA	NULL
binding	NULL
to	NULL
the	NULL
core	NULL
sequence	NULL
GGA	NULL
.	NULL
``	NULL

The	NULL
N-terminal	NULL
part	NULL
of	NULL
the	NULL
protein	NULL
,	NULL
which	NULL
is	NULL
only	NULL
weakly	NULL
or	NULL
not	NULL
at	NULL
all	NULL
homologous	NULL
to	NULL
other	NULL
Ets-proteins	NULL
,	NULL
contains	NULL
a	NULL
glutamine-rich	NULL
transactivation	NULL
domainÂ®	NULL
and	NULL
is	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
TATA-box-binding	NULL
protein	NULL
and	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
Rb	NULL
in	NULL
vitro	NULL
.	NULL
``	NULL

PU.1	NULL
also	NULL
contains	NULL
a	NULL
motif	NULL
that	NULL
mediates	NULL
protein-protein	NULL
interactions	NULL
with	NULL
the	NULL
B-cell-specific	NULL
transcription	NULL
factor	NULL
NF-EMS	NULL
.	NULL
``	NULL

PU.1	NULL
is	NULL
identical	NULL
to	NULL
the	NULL
oncogene	NULL
Spi-1	NULL
implicated	NULL
in	NULL
the	NULL
development	NULL
of	NULL
spleen	NULL
focus-forming	NULL
virus-induced	NULL
murine	NULL
Friend	NULL
erythroleukemia	NULL
.	NULL

Spleen	NULL
focus-forming	NULL
virus	NULL
was	NULL
found	NULL
to	NULL
integrate	NULL
in	NULL
the	NULL
Spi-1	NULL
locus	NULL
in	NULL
95	NULL
%	NULL
of	NULL
the	NULL
tumors	NULL
,	NULL
resulting	NULL
in	NULL
an	NULL
elevated	NULL
expression	NULL
of	NULL
Spi-1	NULL
mRNA	NULL
.	NULL
``	NULL

The	NULL
observations	NULL
that	NULL
overexpression	NULL
of	NULL
Spi-1/PU.1	NULL
immortalizes	NULL
primary	NULL
erythroblasts	NULL
``	NULL
and	NULL
that	NULL
antisense	NULL
oligonucleotides	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
Friend	NULL
murine	NULL
erythroleukemia	NULL
cell	NULL
lines	NULL
``	NULL
further	NULL
indicated	NULL
a	NULL
role	NULL
for	NULL
Spi-1/PU.1	NULL
in	NULL
the	NULL
growth	NULL
control	NULL
of	NULL
immature	NULL
erythroid	NULL
cells	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
Ets-family	NULL
members	NULL
v-Ets	NULL
and	NULL
Fli-1	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
development	NULL
of	NULL
erythroid	NULL
tumors	NULL
in	NULL
chickens	NULL
and	NULL
mice	NULL
,	NULL
respectively	NULL
.	NULL
``	NULL

The	NULL
expression	NULL
of	NULL
PU.1	NULL
in	NULL
mature	NULL
hematopoietic	NULL
cells	NULL
was	NULL
reported	NULL
to	NULL
be	NULL
confined	NULL
to	NULL
B	NULL
cells	NULL
,	NULL
monocytes/macrophages	NULL
,	NULL
and	NULL
mast	NULL
cells	NULL
,	NULL
whereas	NULL
it	NULL
seems	NULL
to	NULL
be	NULL
more	NULL
broadly	NULL
expressed	NULL
at	NULL
early	NULL
stages	NULL
of	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
develop-ment	NULL
.	NULL

**	NULL
``	NULL
*	NULL
``	NULL
This	NULL
would	NULL
also	NULL
agree	NULL
with	NULL
the	NULL
gene-targeting	NULL
data	NULL
which	NULL
suggested	NULL
that	NULL
it	NULL
is	NULL
required	NULL
for	NULL
the	NULL
early	NULL
develop	NULL
Blood	NULL
,	NULL
Vol	NULL
86	NULL
,	NULL
No	NULL
7	NULL
(	NULL
October	NULL
1	NULL
)	NULL
,	NULL
1995	NULL
:	NULL
pp	NULL
2747-2753	NULL
in	NULL
transient	NULL
transfections	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
a	NULL
number	NULL
of	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
,	NULL
representing	NULL
differentiated	NULL
,	NULL
plasma	NULL
cell-like	NULL
B	NULL
cells	NULL
,	NULL
PU.1	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
mRNA	NULL
expression	NULL
,	NULL
and	NULL
Pu	NULL
box-dependent	NULL
transactivation	NULL
were	NULL
absent	NULL
or	NULL
detectable	NULL
at	NULL
a	NULL
very	NULL
low	NULL
level	NULL
.	NULL

In	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
,	NULL
which	NULL
exemplify	NULL
an	NULL
intermediate	NULL
stage	NULL
of	NULL
B-cell	NULL
differentiation	NULL
,	NULL
a	NULL
reduced	NULL
expression	NULL
and	NULL
activity	NULL
were	NULL
observed	NULL
.	NULL

The	NULL
findings	NULL
in	NULL
the	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
represent	NULL
the	NULL
first	NULL
examples	NULL
of	NULL
B	NULL
cells	NULL
with	NULL
downregulated	NULL
PU.1	NULL
expression	NULL
and	NULL
apparently	NULL
contradict	NULL
observations	NULL
in	NULL
the	NULL
murine	NULL
system	NULL
in	NULL
which	NULL
PU.1	NULL
is	NULL
expressed	NULL
and	NULL
active	NULL
in	NULL
plasmacytoma	NULL
cell	NULL
lines	NULL
.	NULL

At	NULL
present	NULL
,	NULL
it	NULL
is	NULL
unclear	NULL
whether	NULL
the	NULL
lack	NULL
of	NULL
PU.1	NULL
expression	NULL
and	NULL
activity	NULL
in	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
represents	NULL
a	NULL
malignancy-associated	NULL
defect	NULL
in	NULL
these	NULL
cells	NULL
or	NULL
exemplifies	NULL
a	NULL
normal	NULL
developmental	NULL
regulation	NULL
in	NULL
terminally	NULL
differentiated	NULL
B	NULL
cells	NULL
.	NULL

Â©	NULL
1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

ment	NULL
of	NULL
several	NULL
lineages	NULL
.	NULL
``	NULL

The	NULL
PU.1	NULL
binding	NULL
site	NULL
,	NULL
the	NULL
so-called	NULL
Pu	NULL
box	NULL
,	NULL
has	NULL
been	NULL
identified	NULL
as	NULL
an	NULL
important	NULL
tissue-specific	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
promoters	NULL
or	NULL
enhancers	NULL
of	NULL
a	NULL
number	NULL
of	NULL
differentiation-associated	NULL
genes	NULL
in	NULL
different	NULL
hematopoietic	NULL
cell	NULL
types	NULL
.	NULL

*	NULL
``	NULL
*	NULL
``	NULL
*	NULL
``	NULL
*	NULL
``	NULL
``	NULL
Thus	NULL
,	NULL
PU.1	NULL
has	NULL
been	NULL
implicated	NULL
as	NULL
an	NULL
important	NULL
tissue-specific	NULL
factor	NULL
regulating	NULL
these	NULL
genes	NULL
in	NULL
intimate	NULL
cooperation	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
such	NULL
as	NULL
NF-EMS	NULL
,	NULL
``	NULL
Â°	NULL
or	NULL
Sp1*	NULL
)	NULL
or	NULL
other	NULL
Ets-family	NULL
members	NULL
(	NULL
such	NULL
as	NULL
Ets1	NULL
,	NULL
``	NULL
Erg-3	NULL
,	NULL
``	NULL
or	NULL
GABPa	NULL
``	NULL
)	NULL
.	NULL

We	NULL
are	NULL
interested	NULL
in	NULL
the	NULL
role	NULL
of	NULL
PU.1	NULL
during	NULL
development	NULL
of	NULL
human	NULL
B-lineage	NULL
cells	NULL
and	NULL
its	NULL
possible	NULL
involvement	NULL
in	NULL
tumor	NULL
formation	NULL
in	NULL
these	NULL
cells	NULL
A	NULL
panel	NULL
of	NULL
human	NULL
B-cell	NULL
lines	NULL
representing	NULL
different	NULL
stages	NULL
of	NULL
development	NULL
,	NULL
from	NULL
early	NULL
precursors	NULL
to	NULL
differentiated	NULL
plasma	NULL
cells	NULL
,	NULL
was	NULL
used	NULL
for	NULL
studies	NULL
of	NULL
PU.1	NULL
expression	NULL
and	NULL
activity	NULL
.	NULL

We	NULL
found	NULL
differences	NULL
in	NULL
PU.1	NULL
mRNA	NULL
expression	NULL
,	NULL
PU.1	NULL
DNA	NULL
binding	NULL
,	NULL
and	NULL
transcriptional	NULL
activity	NULL
in	NULL
cell	NULL
lines	NULL
at	NULL
different	NULL
maturation	NULL
stages	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
we	NULL
can	NULL
show	NULL
that	NULL
PU.1	NULL
activity	NULL
and	NULL
expression	NULL
was	NULL
shut	NULL
off	NULL
in	NULL
a	NULL
panel	NULL
of	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
,	NULL
representing	NULL
differentiated	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
implications	NULL
of	NULL
these	NULL
findings	NULL
will	NULL
be	NULL
discussed	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
.	NULL

-	NULL
All	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Flow	NULL
Laboratories	NULL
,	NULL
Ayrshire	NULL
,	NULL
UK	NULL
)	NULL
supplemented	NULL
with	NULL
7.5	NULL
%	NULL
fetal	NULL
calf	NULL
se	NULL
From	NULL
the	NULL
Laboratory	NULL
of	NULL
Tumor	NULL
Biology	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Uppsala	NULL
,	NULL
University	NULL
Hospital	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
.	NULL

Submitted	NULL
December	NULL
13	NULL
,	NULL
1994	NULL
;	NULL
accepted	NULL
June	NULL
7	NULL
,	NULL
1995	NULL
.	NULL

Supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Swedish	NULL
Cancer	NULL
Society	NULL
,	NULL
T.	NULL
&	NULL
R.	NULL
Soderbergs	NULL
and	NULL
M.	NULL
Bergvalls	NULL
Foundations	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Lars-Gunnar	NULL
Larsson	NULL
,	NULL
PhD	NULL
,	NULL
Laboratory	NULL
of	NULL
Tumor	NULL
Biology	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Uppsala	NULL
,	NULL
Univerisity	NULL
Hospital	NULL
,	NULL
S-751	NULL
85	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

Â©	NULL
1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/95/8607	NULL
2747	NULL
2748	NULL
rum	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
glutamine	NULL
,	NULL
100	NULL
IU/mL	NULL
penicillin	NULL
,	NULL
and	NULL
50	NULL
pg/mL	NULL
streptomycin	NULL
.	NULL

A	NULL
panel	NULL
of	NULL
cell	NULL
lines	NULL
was	NULL
selected	NULL
representing	NULL
different	NULL
stages	NULL
of	NULL
B-cell	NULL
development	NULL
.	NULL

KM3	NULL
is	NULL
derived	NULL
from	NULL
a	NULL
non-B	NULL
,	NULL
non-T	NULL
acute	NULL
lymphocytic	NULL
leukemia	NULL
and	NULL
represents	NULL
a	NULL
lymphoid	NULL
precursor	NULL
cell	NULL
line	NULL
.	NULL
``	NULL

''	NULL
BJA-B	NULL
,	NULL
Raji	NULL
,	NULL
Daudi	NULL
,	NULL
and	NULL
Ramos	NULL
are	NULL
B-lymphoma	NULL
cell	NULL
lines	NULL
representing	NULL
pre-B	NULL
to	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL
``	NULL

Karpas	NULL
422	NULL
and	NULL
MN6O0	NULL
are	NULL
B-lymphoma	NULL
and	NULL
leukemia	NULL
cell	NULL
lines	NULL
,	NULL
respec-tively	NULL
,	NULL
``	NULL
``	NULL
``	NULL
``	NULL
representing	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL

U-255	NULL
and	NULL
Corinna	NULL
II	NULL
are	NULL
lpslun	NULL
Ban	NULL
virus-immortalized	NULL
Ig-secreting	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
,	NULL
``	NULL
``	NULL
representing	NULL
B	NULL
cells	NULL
at	NULL
the	NULL
B-blast/immunoblast	NULL
stage	NULL
.	NULL

Karpas	NULL
707	NULL
,	NULL
L363	NULL
,	NULL
U-1996	NULL
,	NULL
and	NULL
U-266	NULL
are	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
``	NULL
``	NULL
and	NULL
represent	NULL
plasmablasts-plasma	NULL
cells	NULL
.	NULL

U-266-1970	NULL
and	NULL
U-266-1984	NULL
are	NULL
early	NULL
and	NULL
late	NULL
passages	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
an	NULL
IgE	NULL
myeloma	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
phenotype	NULL
of	NULL
which	NULL
has	NULL
been	NULL
described	NULL
.	NULL
``	NULL

Transfection	NULL
and	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
assay	NULL
.	NULL

Transfections	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
diethyl	NULL
aminoethyl	NULL
(	NULL
DEAE	NULL
)	NULL
-dextran	NULL
method	NULL
.	NULL
``	NULL

The	NULL
cells	NULL
were	NULL
fed	NULL
24	NULL
hours	NULL
before	NULL
transfection	NULL
,	NULL
and	NULL
20	NULL
x	NULL
10Â°	NULL
cells	NULL
were	NULL
mixed	NULL
with	NULL
a	NULL
solution	NULL
containing	NULL
300	NULL
ug	NULL
DEAE-dextran	NULL
(	NULL
Pharmacia	NULL
,	NULL
Sollentuna	NULL
,	NULL
Sweden	NULL
)	NULL
and	NULL
5	NULL
ug	NULL
DNA	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
followed	NULL
by	NULL
glycerol	NULL
treatment	NULL
for	NULL
3	NULL
minutes	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
before	NULL
fresh	NULL
medium	NULL
was	NULL
added	NULL
.	NULL

Seventy-two	NULL
hours	NULL
postinfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
a	NULL
CAT	NULL
assay	NULL
was	NULL
performed	NULL
.	NULL
``	NULL

Nuclear	NULL
extracts	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
40	NULL
x	NULL
10Â°	NULL
cells	NULL
using	NULL
the	NULL
lysolec-ithin	NULL
procedure	NULL
described	NULL
by	NULL
Zervitz	NULL
and	NULL
Akusjirvi	NULL
.	NULL

'Â®	NULL
Ten	NULL
micro-grams	NULL
of	NULL
extract	NULL
was	NULL
used	NULL
for	NULL
each	NULL
binding	NULL
reaction	NULL
,	NULL
and	NULL
1	NULL
pg	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
)	NULL
and	NULL
10	NULL
pmol	NULL
single-stranded	NULL
oligonucleotide	NULL
were	NULL
included	NULL
as	NULL
nonspecific	NULL
competitors	NULL
.	NULL

EMSA	NULL
with	NULL
the	NULL
Pu	NULL
box	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
10	NULL
mmol/L	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
20	NULL
mmol/L	NULL
KCI	NULL
,	NULL
4	NULL
mmol/L	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
0.25	NULL
mmol/L	NULL
dithiotreitol	NULL
,	NULL
4	NULL
mmol/L	NULL
spermidine	NULL
,	NULL
and	NULL
100	NULL
pg/mL	NULL
bovine	NULL
serum	NULL
albumin	NULL
.	NULL

The	NULL
Spl	NULL
EMSA	NULL
was	NULL
performed	NULL
in	NULL
10	NULL
mmol/L	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
50	NULL
mmol/L	NULL
KCI	NULL
,	NULL
5	NULL
mmol/L	NULL
MgCl	NULL
,	NULL
,	NULL
0.6	NULL
mmol/L	NULL
dithiotreitol	NULL
,	NULL
and	NULL
200	NULL
pmol/L	NULL
ZnS	NULL
$	NULL
O	NULL
,	NULL
.	NULL

The	NULL
extract	NULL
was	NULL
added	NULL
to	NULL
the	NULL
buffer	NULL
including	NULL
the	NULL
nonspecific	NULL
competitor	NULL
and	NULL
was	NULL
incubated	NULL
for	NULL
20	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Pu	NULL
box	NULL
or	NULL
the	NULL
SpI	NULL
oligonucleotide	NULL
(	NULL
1	NULL
to	NULL
2	NULL
fmol	NULL
)	NULL
,	NULL
end-labeled	NULL
with	NULL
Klenow	NULL
DNA	NULL
polymerase	NULL
or	NULL
T4	NULL
DNA	NULL
polynucleotidekinase	NULL
,	NULL
respectively	NULL
,	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
further	NULL
incubated	NULL
for	NULL
20	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.25	NULL
%	NULL
TBE	NULL
(	NULL
0.022	NULL
mol/L	NULL
Tris-borate	NULL
and	NULL
0.5	NULL
mmol/L	NULL
EDTA	NULL
)	NULL
.	NULL

The	NULL
Pu	NULL
box	NULL
oligonucleotide	NULL
sequence	NULL
(	NULL
5TCGACT-CTGAAAGAGGAACTCTCGAGCT	NULL
)	NULL
is	NULL
derived	NULL
from	NULL
the	NULL
SV40	NULL
control	NULL
region	NULL
.	NULL
'	NULL

The	NULL
mutated	NULL
Pu	NULL
box	NULL
sequence	NULL
is	NULL
S5'TCGACT-CGTCCAGAGGAACTCTCGAGCT	NULL
.	NULL

The	NULL
Spl	NULL
oligonucleotide	NULL
(	NULL
5Â°CCGGCCCCGCccaATCCcccGGCcccGccCaATCC	NULL
)	NULL
contains	NULL
a	NULL
dimer	NULL
of	NULL
a	NULL
binding	NULL
site	NULL
found	NULL
in	NULL
the	NULL
immediate	NULL
early	NULL
gene	NULL
3	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
.	NULL

Antibody	NULL
1297	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
van	NULL
Beveren	NULL
,	NULL
La	NULL
Jolla	NULL
Cancer	NULL
Research	NULL
Foundation	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
is	NULL
specific	NULL
for	NULL
the	NULL
N-terminal	NULL
region	NULL
of	NULL
PU.1	NULL
,	NULL
and	NULL
antibody	NULL
T-21	NULL
(	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
recognizes	NULL
the	NULL
C-terminal	NULL
part	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Plasmid	NULL
constructions	NULL
.	NULL

_	NULL
pCAT-Control	NULL
plasmid	NULL
(	NULL
Promega	NULL
,	NULL
Madi-son	NULL
,	NULL
WI	NULL
)	NULL
with	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
and	NULL
enhancer	NULL
sequences	NULL
served	NULL
as	NULL
the	NULL
control	NULL
plasmid	NULL
in	NULL
the	NULL
transfection	NULL
experiments	NULL
.	NULL

An	NULL
Xho	NULL
1	NULL
linker	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
Be/	NULL
II	NULL
site	NULL
of	NULL
pCAT-Promoter	NULL
plasmid	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
the	NULL
new	NULL
plasmid	NULL
was	NULL
designated	NULL
pPromXCAT	NULL
.	NULL

Four	NULL
copies	NULL
of	NULL
the	NULL
Pu	NULL
box	NULL
oligonucleotides	NULL
(	NULL
wild-type	NULL
and	NULL
mumlud	NULL
)	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
oligonucleotide	NULL
vector	NULL
(	NULL
OVEC	NULL
)	NULL
plas-mid	NULL
.	NULL
``	NULL

The	NULL
resulting	NULL
Xho	NULL
I-Sal	NULL
I	NULL
fragment	NULL
was	NULL
then	NULL
inserted	NULL
into	NULL
the	NULL
Xho	NULL
I	NULL
site	NULL
of	NULL
pPromXCAT	NULL
.	NULL

Northern	NULL
analysis	NULL
.	NULL

-	NULL
Total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
exponentially	NULL
growing	NULL
cells	NULL
by	NULL
the	NULL
LiCl/urea	NULL
method	NULL
.	NULL
``	NULL

''	NULL
RNA	NULL
(	NULL
15	NULL
Lg	NULL
)	NULL
was	NULL
denatur-ated	NULL
in	NULL
formamide	NULL
and	NULL
fractionated	NULL
in	NULL
an	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
containing	NULL
PETTERSSON	NULL
ET	NULL
AL	NULL
A	NULL
B	NULL
wth	NULL
-	NULL
a	NULL
Â«	NULL
wile	NULL
waue	NULL
b	NULL
2	NULL
3	NULL
4	NULL
5	NULL
Fig	NULL
1	NULL
.	NULL

-	NULL
EMSA	NULL
with	NULL
the	NULL
Pu	NULL
box	NULL
sequence	NULL
.	NULL

The	NULL
SV40	NULL
Pu	NULL
box	NULL
oligonucleotide	NULL
was	NULL
mixed	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
BJA-B	NULL
nuclear	NULL
extract	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
complexes	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Lane	NULL
1	NULL
,	NULL
no	NULL
extract	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
with	NULL
extract	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
complexes	NULL
was	NULL
analyzed	NULL
by	NULL
addition	NULL
of	NULL
a	NULL
500-fold	NULL
molar	NULL
excess	NULL
of	NULL
cold	NULL
Pu	NULL
box	NULL
sequence	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
a	NULL
mutated	NULL
Pu	NULL
box	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
Sp1	NULL
binding	NULL
site	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
main	NULL
Pu	NULL
box/protein	NULL
complexes	NULL
formed	NULL
are	NULL
indicated	NULL
as	NULL
a	NULL
and	NULL
b	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Supershift	NULL
performed	NULL
with	NULL
an	NULL
antibody	NULL
directed	NULL
against	NULL
the	NULL
N-terminal	NULL
part	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
no	NULL
extract	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
extract	NULL
without	NULL
anti-body	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
antibody	NULL
added	NULL
.	NULL

formaldehyde	NULL
(	NULL
4	NULL
mL/100	NULL
mL	NULL
gel	NULL
)	NULL
.	NULL

After	NULL
electrophoresis	NULL
,	NULL
the	NULL
RNA	NULL
was	NULL
transferred	NULL
to	NULL
a	NULL
nitrocellulose	NULL
filter	NULL
.	NULL

The	NULL
probes	NULL
were	NULL
P-labeled	NULL
by	NULL
the	NULL
random	NULL
priming	NULL
method	NULL
(	NULL
Amersham	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

Hybridization	NULL
was	NULL
performed	NULL
at	NULL
42Â°C	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
1	NULL
%	NULL
Denhardt	NULL
's	NULL
solution	NULL
,	NULL
2	NULL
%	NULL
SSC	NULL
(	NULL
2	NULL
%	NULL
SSC	NULL
:	NULL
0.3	NULL
mol/L	NULL
sodium	NULL
chloride	NULL
and	NULL
30	NULL
mmol/L	NULL
sodium	NULL
citrate	NULL
)	NULL
,	NULL
5	NULL
mmol/L	NULL
NaPO	NULL
,	NULL
,	NULL
0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
,	NULL
and	NULL
200	NULL
pg/mL	NULL
of	NULL
salmon	NULL
sperm	NULL
DNA	NULL
.	NULL

Filters	NULL
were	NULL
washed	NULL
in	NULL
0.5	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
and	NULL
2	NULL
%	NULL
SSC	NULL
at	NULL
50Â°C	NULL
and	NULL
exposed	NULL
to	NULL
Kodak	NULL
XAR	NULL
film	NULL
(	NULL
Eastman	NULL
Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

A	NULL
murine	NULL
PU.1	NULL
cDNA	NULL
clone	NULL
(	NULL
unpublished	NULL
,	NULL
Dr	NULL
L.	NULL
Hellman	NULL
,	NULL
Department	NULL
of	NULL
Medical	NULL
Immunology	NULL
and	NULL
Microbiology	NULL
,	NULL
University	NULL
of	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
and	NULL
a	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
cDNA	NULL
clone	NULL
``	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
.	NULL

RESULTS	NULL
Absence	NULL
of	NULL
PU.1	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

To	NULL
establish	NULL
the	NULL
conditions	NULL
for	NULL
studies	NULL
of	NULL
PU.1	NULL
DNA	NULL
binding	NULL
,	NULL
we	NULL
used	NULL
the	NULL
human	NULL
BJA-B	NULL
cell	NULL
line	NULL
known	NULL
to	NULL
express	NULL
PU.1.3	NULL
A	NULL
P-labeled	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
Pu	NULL
box	NULL
sequence	NULL
from	NULL
the	NULL
SV40	NULL
control	NULL
region	NULL
was	NULL
mixed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
BJA-B	NULL
cells	NULL
and	NULL
analyzed	NULL
by	NULL
EMSA	NULL
.	NULL

The	NULL
SV40	NULL
Pu	NULL
box	NULL
binds	NULL
PU.1	NULL
with	NULL
high	NULL
affinity	NULL
but	NULL
is	NULL
a	NULL
poor	NULL
binding	NULL
site	NULL
for	NULL
many	NULL
other	NULL
Ets-family	NULL
proteins	NULL
.	NULL
``	NULL

''	NULL
``	NULL
Figure	NULL
1A	NULL
shows	NULL
that	NULL
two	NULL
major	NULL
retarded	NULL
com-plexes	NULL
,	NULL
a	NULL
and	NULL
b	NULL
,	NULL
were	NULL
formed	NULL
.	NULL

These	NULL
complexes	NULL
were	NULL
competed	NULL
by	NULL
an	NULL
access	NULL
unlabeled	NULL
Pu	NULL
box	NULL
oligonucleotide	NULL
but	NULL
not	NULL
by	NULL
a	NULL
mutated	NULL
oligonucleotide	NULL
or	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
an	NULL
Spl	NULL
binding	NULL
site	NULL
,	NULL
thus	NULL
showing	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
binding	NULL
.	NULL

The	NULL
mutated	NULL
oligonucleotide	NULL
,	NULL
previously	NULL
shown	NULL
to	NULL
eliminate	NULL
binding	NULL
of	NULL
PU.1	NULL
,	NULL
``	NULL
contains	NULL
4	NULL
substitutions	NULL
4-7	NULL
PU.1	NULL
EXPRESSION	NULL
IN	NULL
HUMAN	NULL
B	NULL
CELLS	NULL
Fig	NULL
2	NULL
.	NULL

PU.1	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
.	NULL

EMSA	NULL
using	NULL
the	NULL
Pu	NULL
box	NULL
oligonucleotide	NULL
was	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
the	NULL
following	NULL
B-cell	NULL
lines	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
no	NULL
extract	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
KM3	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
BJA-B	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
Daudi	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
Raji	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
Ramos	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
Karpas	NULL
422	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
MN6O	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
U-255	NULL
;	NULL
lane	NULL
10	NULL
,	NULL
Corinna	NULL
II	NULL
;	NULL
lane	NULL
11	NULL
,	NULL
Karpas	NULL
707	NULL
;	NULL
lane	NULL
12	NULL
,	NULL
L363	NULL
;	NULL
lane	NULL
13	NULL
,	NULL
U-1996	NULL
;	NULL
lane	NULL
14	NULL
,	NULL
U-266-1970	NULL
;	NULL
and	NULL
lane	NULL
15	NULL
,	NULL
U-266-1984	NULL
.	NULL

nucleotides	NULL
5Â°	NULL
of	NULL
the	NULL
the	NULL
GGA	NULL
core	NULL
binding	NULL
site	NULL
for	NULL
Ets-family	NULL
proteins	NULL
.	NULL

Addition	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
of	NULL
antibodies	NULL
directed	NULL
to	NULL
the	NULL
N-terminus	NULL
of	NULL
PU.1	NULL
resulted	NULL
in	NULL
a	NULL
supershift	NULL
of	NULL
the	NULL
upper	NULL
but	NULL
not	NULL
the	NULL
lower	NULL
Pu	NULL
box	NULL
binding	NULL
complex	NULL
,	NULL
thus	NULL
confirming	NULL
the	NULL
presence	NULL
of	NULL
PU.1	NULL
or	NULL
an	NULL
antigenically	NULL
closely	NULL
related	NULL
protein	NULL
in	NULL
the	NULL
former	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

Addition	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
of	NULL
antibodies	NULL
specific	NULL
for	NULL
the	NULL
C-terminus	NULL
of	NULL
PU	NULL
.	NULL

1	NULL
prevented	NULL
formation	NULL
of	NULL
both	NULL
the	NULL
upper	NULL
and	NULL
lower	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
lower	NULL
complex	NULL
represents	NULL
a	NULL
degradation	NULL
product	NULL
of	NULL
PU.1	NULL
containing	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
but	NULL
lacking	NULL
the	NULL
N-terminal	NULL
antibody-binding	NULL
epitope	NULL
.	NULL

PU.1	NULL
contains	NULL
a	NULL
so-called	NULL
PEST	NULL
sequence	NULL
suggested	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
protein	NULL
degradation	NULL
.	NULL

**	NULL
``	NULL
To	NULL
investigate	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
PU.1	NULL
in	NULL
relation	NULL
to	NULL
B-cell	NULL
differentiation	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
various	NULL
human	NULL
B-cell	NULL
lines	NULL
representing	NULL
different	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
.	NULL

These	NULL
included	NULL
the	NULL
pro-B-cell	NULL
line	NULL
KM3	NULL
;	NULL
the	NULL
B-lymphoma	NULL
cell	NULL
lines	NULL
BJA-B	NULL
,	NULL
Raji	NULL
,	NULL
Daudi	NULL
,	NULL
and	NULL
Ramos	NULL
representing	NULL
pre-B	NULL
to	NULL
mature	NULL
B	NULL
cells	NULL
;	NULL
the	NULL
Karpas	NULL
422	NULL
follicular	NULL
lymphoma	NULL
cell	NULL
line	NULL
and	NULL
B-leukemia	NULL
cell	NULL
line	NULL
MN6O0	NULL
representing	NULL
mature	NULL
B	NULL
cells	NULL
;	NULL
the	NULL
U-255	NULL
and	NULL
Corinna	NULL
II	NULL
Ig-secreting	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
and	NULL
,	NULL
finally	NULL
,	NULL
the	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
Karpas	NULL
707	NULL
,	NULL
L363	NULL
,	NULL
U-1996	NULL
,	NULL
U-266-1970	NULL
,	NULL
and	NULL
U-266-1984	NULL
representing	NULL
plasmablasts-plasma	NULL
cells	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
using	NULL
the	NULL
Pu	NULL
box	NULL
sequence	NULL
as	NULL
above	NULL
.	NULL

Figure	NULL
2	NULL
shows	NULL
that	NULL
a	NULL
Pu	NULL
box-binding	NULL
complex	NULL
comigrating	NULL
with	NULL
the	NULL
upper	NULL
PU.1	NULL
complex	NULL
in	NULL
BJA-B	NULL
cells	NULL
was	NULL
clearly	NULL
shown	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
representing	NULL
early	NULL
and	NULL
mature	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
lanes	NULL
2-8	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
three	NULL
of	NULL
the	NULL
myeloma	NULL
cell	NULL
lines	NULL
,	NULL
U-1996	NULL
,	NULL
U-266-1970	NULL
,	NULL
and	NULL
U-266-1984	NULL
,	NULL
were	NULL
completely	NULL
negative	NULL
;	NULL
in	NULL
the	NULL
other	NULL
two	NULL
,	NULL
L363	NULL
and	NULL
Karpas	NULL
707	NULL
,	NULL
a	NULL
very	NULL
faint	NULL
band	NULL
could	NULL
be	NULL
detected	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
lanes	NULL
11-15	NULL
)	NULL
.	NULL

Compared	NULL
with	NULL
early	NULL
and	NULL
mature	NULL
B-cell	NULL
lines	NULL
,	NULL
a	NULL
reduced	NULL
PU.1	NULL
binding	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
,	NULL
in	NULL
particular	NULL
in	NULL
Corinna	NULL
II	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Figure	NULL
3	NULL
shows	NULL
that	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
an	NULL
Spl	NULL
binding	NULL
site	NULL
showed	NULL
specific	NULL
Spl	NULL
binding	NULL
activity	NULL
in	NULL
the	NULL
myeloma	NULL
cell	NULL
extracts	NULL
as	NULL
well	NULL
as	NULL
in	NULL
BJA-B	NULL
extracts	NULL
,	NULL
thus	NULL
ruling	NULL
out	NULL
a	NULL
general	NULL
degradation	NULL
of	NULL
the	NULL
myeloma	NULL
extracts	NULL
.	NULL

Absence	NULL
of	NULL
Pu	NULL
box-dependent	NULL
transcriptional	NULL
activity	NULL
in	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
2749	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

_	NULL
We	NULL
next	NULL
investigated	NULL
whether	NULL
the	NULL
observed	NULL
binding	NULL
of	NULL
PU.1	NULL
to	NULL
the	NULL
Pu	NULL
box	NULL
in	NULL
the	NULL
various	NULL
extracts	NULL
correlated	NULL
with	NULL
transcriptional	NULL
activity	NULL
.	NULL

Four	NULL
copies	NULL
of	NULL
the	NULL
Pu	NULL
box	NULL
oligonucleotide	NULL
and	NULL
a	NULL
mutated	NULL
version	NULL
thereof	NULL
were	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
in	NULL
a	NULL
CAT	NULL
gene	NULL
construct	NULL
.	NULL

The	NULL
plasmids	NULL
were	NULL
transfected	NULL
into	NULL
selected	NULL
B-cell	NULL
lines	NULL
,	NULL
and	NULL
,	NULL
72	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

A	NULL
construct	NULL
with	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
and	NULL
enhancer	NULL
sequences	NULL
was	NULL
H	NULL
MUN-	NULL
u	NULL
h	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
T7	NULL
8	NULL
Fig	NULL
3	NULL
.	NULL

Sp1	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
.	NULL

An	NULL
oligonucleotide	NULL
containing	NULL
two	NULL
Sp1	NULL
binding	NULL
sites	NULL
was	NULL
mixed	NULL
with	NULL
the	NULL
following	NULL
B-cell	NULL
extracts	NULL
and	NULL
subjected	NULL
to	NULL
EMSA	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
no	NULL
extract	NULL
;	NULL
lane	NULL
2	NULL
and	NULL
3	NULL
,	NULL
BJA-B	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
Karpas	NULL
707	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
L363	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
U-1996	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
U-266-1970	NULL
;	NULL
and	NULL
lane	NULL
8	NULL
,	NULL
U-266-1984	NULL
.	NULL

In	NULL
lane	NULL
3	NULL
,	NULL
a	NULL
500-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
Sp1	NULL
sequence	NULL
is	NULL
included	NULL
in	NULL
the	NULL
mixture	NULL
.	NULL

2750	NULL
form	NULL
m	NULL
thir	NULL
trie	NULL
i	NULL
transfected	NULL
in	NULL
parallel	NULL
and	NULL
served	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

In	NULL
the	NULL
BJA-B	NULL
,	NULL
Raji	NULL
,	NULL
U-255	NULL
,	NULL
and	NULL
Karpas	NULL
422	NULL
cell	NULL
lines	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
Pu	NULL
boxes	NULL
led	NULL
to	NULL
an	NULL
enhanced	NULL
transcription	NULL
from	NULL
the	NULL
CAT	NULL
gene	NULL
to	NULL
various	NULL
degrees	NULL
,	NULL
whereas	NULL
mutations	NULL
introduced	NULL
in	NULL
the	NULL
Pu	NULL
box	NULL
reduced	NULL
the	NULL
activity	NULL
to	NULL
basal	NULL
level	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

Densitometrical	NULL
scanning	NULL
of	NULL
the	NULL
autoradiogram	NULL
and	NULL
normalizing	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
pPromXCAT	NULL
vector	NULL
lacking	NULL
Pu	NULL
boxes	NULL
showed	NULL
that	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
Pu	NULL
box	NULL
stimulated	NULL
transcription	NULL
28	NULL
times	NULL
in	NULL
BJA-B	NULL
cells	NULL
,	NULL
8	NULL
times	NULL
in	NULL
Raji	NULL
cells	NULL
,	NULL
and	NULL
3	NULL
times	NULL
in	NULL
U-255	NULL
and	NULL
Karpas	NULL
422	NULL
cells	NULL
.	NULL

Transfection	NULL
of	NULL
the	NULL
myeloma	NULL
cell	NULL
lines	NULL
L363	NULL
and	NULL
U-266-1984	NULL
with	NULL
the	NULL
Pu	NULL
box-containing	NULL
plasmids	NULL
did	NULL
not	NULL
lead	NULL
to	NULL
activation	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
,	NULL
thus	NULL
correlating	NULL
with	NULL
the	NULL
lack	NULL
of	NULL
Pu	NULL
box	NULL
binding	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

A	NULL
control	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
containing	NULL
SV40	NULL
promoter	NULL
and	NULL
enhancer	NULL
sequences	NULL
strongly	NULL
stimulated	NULL
transcription	NULL
in	NULL
the	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
were	NULL
also	NULL
unable	NULL
to	NULL
detect	NULL
any	NULL
Pu	NULL
box-dependent	NULL
transcriptional	NULL
activity	NULL
in	NULL
the	NULL
Corinna	NULL
II	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
has	NULL
a	NULL
reduced	NULL
PU.1	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
PU.1	NULL
gene	NULL
is	NULL
downregulated	NULL
in	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

-	NULL
The	NULL
lack	NULL
of	NULL
PU.1	NULL
activity	NULL
in	NULL
the	NULL
myeloma	NULL
cells	NULL
could	NULL
be	NULL
because	NULL
of	NULL
a	NULL
downregulation	NULL
of	NULL
the	NULL
PU.1	NULL
gene	NULL
expression	NULL
or	NULL
,	NULL
alternatively	NULL
,	NULL
because	NULL
the	NULL
protein	NULL
is	NULL
present	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
expression	NULL
of	NULL
PU.1	NULL
in	NULL
the	NULL
panel	NULL
of	NULL
B-cell	NULL
lines	NULL
used	NULL
above	NULL
,	NULL
RNA	NULL
was	NULL
prepared	NULL
,	NULL
and	NULL
a	NULL
Northern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
mouse	NULL
PU.1	NULL
cDNA	NULL
as	NULL
probe	NULL
.	NULL

Figure	NULL
5A	NULL
shows	NULL
that	NULL
the	NULL
1.4-kb	NULL
PU.1	NULL
transcript	NULL
was	NULL
expressed	NULL
in	NULL
all	NULL
B-cell	NULL
lines	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
the	NULL
myeloma	NULL
cell	NULL
lines	NULL
,	NULL
in	NULL
which	NULL
it	NULL
was	NULL
undetectable	NULL
even	NULL
after	NULL
prolonged	NULL
exposure	NULL
.	NULL

The	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
U-255	NULL
showed	NULL
a	NULL
reduced	NULL
expression	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
PU.1	NULL
mRNA	NULL
was	NULL
very	NULL
low	NULL
,	NULL
but	NULL
detectable	NULL
,	NULL
in	NULL
Corinna	NULL
II	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
the	NULL
same	NULL
filter	NULL
was	NULL
rehybridized	NULL
with	NULL
a	NULL
GAPDH	NULL
probe	NULL
,	NULL
showing	NULL
that	NULL
this	NULL
gene	NULL
was	NULL
expressed	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
5B	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
PU.1	NULL
gene	NULL
is	NULL
shut	NULL
off	NULL
in	NULL
the	NULL
myeloma	NULL
PETTERSSON	NULL
ET	NULL
AL	NULL
t11	NULL
?	NULL

Fig	NULL
4	NULL
.	NULL

Pu	NULL
box-dependent	NULL
transcriptional	NULL
activity	NULL
in	NULL
human	NULL
B-cell	NULL
lines	NULL
.	NULL

The	NULL
various	NULL
B-cell	NULL
lines	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
mg	NULL
of	NULL
the	NULL
CAT	NULL
reporter	NULL
plasmids	NULL
described	NULL
below	NULL
using	NULL
DEAE-dextran	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
3	NULL
days	NULL
,	NULL
and	NULL
transcriptional	NULL
activity	NULL
was	NULL
analyzed	NULL
by	NULL
CAT	NULL
assay	NULL
.	NULL

(	NULL
A	NULL
)	NULL
CAT	NULL
assay	NULL
performed	NULL
without	NULL
extract	NULL
(	NULL
0	NULL
)	NULL
and	NULL
with	NULL
purified	NULL
CAT	NULL
(	NULL
E	NULL
)	NULL
.	NULL

The	NULL
following	NULL
cell	NULL
lines	NULL
were	NULL
used	NULL
:	NULL
B	NULL
,	NULL
BJA-B	NULL
;	NULL
C	NULL
,	NULL
Raji	NULL
;	NULL
D	NULL
,	NULL
Karpas	NULL
422	NULL
;	NULL
E	NULL
,	NULL
U-255	NULL
;	NULL
F	NULL
,	NULL
Corinna	NULL
II	NULL
;	NULL
G	NULL
,	NULL
U-266-1984	NULL
;	NULL
H	NULL
,	NULL
L363	NULL
.	NULL

Reporter	NULL
plasmids	NULL
were	NULL
used	NULL
as	NULL
follows	NULL
:	NULL
in	NULL
lane	NULL
1	NULL
is	NULL
pPromXCAT	NULL
containing	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
but	NULL
lacking	NULL
Pu	NULL
boxes	NULL
.	NULL

In	NULL
lane	NULL
2	NULL
,	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
Pu	NULL
box	NULL
are	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
in	NULL
pPromXCAT	NULL
,	NULL
and	NULL
lane	NULL
3	NULL
contains	NULL
,	NULL
in	NULL
a	NULL
similar	NULL
way	NULL
,	NULL
four	NULL
copies	NULL
of	NULL
a	NULL
mutated	NULL
Pu	NULL
box	NULL
.	NULL

Lane	NULL
4	NULL
is	NULL
the	NULL
pCAT-Control	NULL
(	NULL
Promega	NULL
)	NULL
with	NULL
SV40	NULL
early	NULL
promoter	NULL
and	NULL
enhancer	NULL
.	NULL

Â»	NULL
+t+	NULL
#	NULL
cell	NULL
lines	NULL
,	NULL
thus	NULL
explaining	NULL
activity	NULL
and	NULL
DNA	NULL
binding	NULL
the	NULL
lack	NULL
of	NULL
PU.1	NULL
transcriptional	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
PU.1	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
specific	NULL
for	NULL
hematopoietic	NULL
cells	NULL
that	NULL
seems	NULL
to	NULL
be	NULL
required	NULL
for	NULL
development	NULL
of	NULL
early	NULL
1	NULL
2	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Fig	NULL
5	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
PU.1	NULL
expression	NULL
in	NULL
human	NULL
B-cell	NULL
lines	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
prepared	NULL
from	NULL
11	NULL
different	NULL
B-cell	NULL
lines	NULL
and	NULL
fractionated	NULL
on	NULL
a	NULL
formaldehyde-containing	NULL
agarose	NULL
gel	NULL
.	NULL

After	NULL
blotting	NULL
onto	NULL
nitrocellulose	NULL
filter	NULL
,	NULL
hybridization	NULL
was	NULL
performed	NULL
using	NULL
*Â°P-la-beled	NULL
probes	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
KM3	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
BJA-B	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
Daudi	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
Raji	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
Karpas	NULL
422	NULL
;	NULL
lane	NULL
6	NULL
MN6O0	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
U-255	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
Corinna	NULL
II	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
L363	NULL
;	NULL
lane	NULL
10	NULL
,	NULL
U-1996	NULL
;	NULL
lane	NULL
11	NULL
,	NULL
U-266-1984	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
murine	NULL
PU.1	NULL
cDNA	NULL
clone	NULL
was	NULL
used	NULL
as	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Hybridized	NULL
probe	NULL
was	NULL
removed	NULL
,	NULL
and	NULL
the	NULL
filter	NULL
was	NULL
rehybridized	NULL
with	NULL
a	NULL
GAPDH	NULL
probe	NULL
.	NULL

PU.1	NULL
EXPRESSION	NULL
IN	NULL
HUMAN	NULL
B	NULL
CELLS	NULL
precursor	NULL
cells	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
suggested	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
and	NULL
macrophages	NULL
.	NULL

We	NULL
have	NULL
undertaken	NULL
a	NULL
study	NULL
to	NULL
investigate	NULL
the	NULL
presence	NULL
and	NULL
activity	NULL
of	NULL
PU.1	NULL
during	NULL
human	NULL
B-cell	NULL
development	NULL
using	NULL
a	NULL
panel	NULL
of	NULL
human	NULL
B-cell	NULL
lines	NULL
representing	NULL
the	NULL
B-cell	NULL
lineage	NULL
from	NULL
early	NULL
precursors	NULL
to	NULL
differentiated	NULL
plasma	NULL
cells	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
major	NULL
differences	NULL
in	NULL
the	NULL
expression	NULL
and	NULL
activity	NULL
of	NULL
PU.1	NULL
in	NULL
cell	NULL
lines	NULL
representing	NULL
different	NULL
levels	NULL
of	NULL
B-cell	NULL
development	NULL
.	NULL

PU.1	NULL
mRNA	NULL
expression	NULL
and	NULL
PU.1	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
shown	NULL
in	NULL
the	NULL
pro-B-cell	NULL
line	NULL
KM3	NULL
as	NULL
well	NULL
as	NULL
in	NULL
pre-B	NULL
and	NULL
mature	NULL
B-cell	NULL
lines	NULL
.	NULL

Pu	NULL
box-dependent	NULL
transcriptional	NULL
activity	NULL
of	NULL
a	NULL
CAT	NULL
reporter	NULL
gene	NULL
was	NULL
also	NULL
shown	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
in	NULL
transient	NULL
transfections	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
a	NULL
panel	NULL
of	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
representing	NULL
differentiated	NULL
B	NULL
cells	NULL
,	NULL
no	NULL
or	NULL
only	NULL
very	NULL
low	NULL
mRNA	NULL
expression	NULL
,	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
and	NULL
Pu	NULL
box-dependent	NULL
transactivation	NULL
were	NULL
detectable	NULL
.	NULL

A	NULL
reduced	NULL
PU.1	NULL
activity	NULL
and	NULL
expression	NULL
were	NULL
observed	NULL
in	NULL
the	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
U-255	NULL
and	NULL
Corinna	NULL
II	NULL
,	NULL
representing	NULL
an	NULL
intermediate	NULL
stage	NULL
of	NULL
differentiation	NULL
.	NULL

This	NULL
reduction	NULL
was	NULL
most	NULL
pronounced	NULL
in	NULL
Corinna	NULL
II	NULL
,	NULL
which	NULL
seems	NULL
further	NULL
differentiated	NULL
than	NULL
many	NULL
other	NULL
Epstein-Barr	NULL
virus-transformed	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
in	NULL
that	NULL
it	NULL
lacks	NULL
CD37	NULL
expression	NULL
(	NULL
our	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Corinna	NULL
H	NULL
is	NULL
clearly	NULL
less	NULL
differentiated	NULL
than	NULL
the	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
Our	NULL
observations	NULL
in	NULL
human	NULL
pro-B	NULL
,	NULL
pre-B	NULL
and	NULL
mature	NULL
B	NULL
cells	NULL
are	NULL
in	NULL
good	NULL
agreement	NULL
with	NULL
previous	NULL
studies	NULL
in	NULL
murine	NULL
B-cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
PU.1	NULL
expression	NULL
and	NULL
activity	NULL
in	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
is	NULL
a	NULL
unique	NULL
finding	NULL
and	NULL
represents	NULL
the	NULL
first	NULL
example	NULL
of	NULL
B	NULL
cells	NULL
with	NULL
downregulated	NULL
PU.1	NULL
expression	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
apparently	NULL
contradictory	NULL
to	NULL
results	NULL
obtained	NULL
in	NULL
the	NULL
murine	NULL
system	NULL
,	NULL
in	NULL
which	NULL
PU.1	NULL
is	NULL
expressed	NULL
and	NULL
active	NULL
in	NULL
most	NULL
plasmacytoma	NULL
cell	NULL
lines	NULL
.	NULL

*	NULL
``	NULL
``	NULL
*	NULL
``	NULL
Our	NULL
finding	NULL
in	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
may	NULL
be	NULL
interpreted	NULL
in	NULL
at	NULL
least	NULL
two	NULL
different	NULL
ways	NULL
.	NULL

(	NULL
1	NULL
)	NULL
Because	NULL
PU.1	NULL
seems	NULL
generally	NULL
expressed	NULL
in	NULL
other	NULL
B	NULL
cells	NULL
,	NULL
one	NULL
interpretation	NULL
is	NULL
that	NULL
the	NULL
lack	NULL
of	NULL
PU.1	NULL
is	NULL
a	NULL
malignancy-associated	NULL
defect	NULL
common	NULL
to	NULL
human	NULL
multiple	NULL
myeloma	NULL
.	NULL

If	NULL
PU.1	NULL
is	NULL
an	NULL
important	NULL
transcription	NULL
factor	NULL
involved	NULL
in	NULL
commitment	NULL
along	NULL
the	NULL
B	NULL
lineage	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
loss	NULL
of	NULL
PU.1	NULL
may	NULL
result	NULL
in	NULL
problems	NULL
for	NULL
the	NULL
cell	NULL
to	NULL
recognize	NULL
itself	NULL
as	NULL
a	NULL
B	NULL
cell	NULL
,	NULL
and	NULL
,	NULL
thus	NULL
,	NULL
it	NULL
may	NULL
be	NULL
unable	NULL
to	NULL
complete	NULL
the	NULL
differentiation	NULL
program	NULL
and	NULL
develop	NULL
into	NULL
terminally	NULL
differentiated	NULL
,	NULL
resting	NULL
plasma	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
from	NULL
Southern	NULL
analysis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
cytogenetic	NULL
analysis	NULL
of	NULL
chromosome	NULL
11	NULL
,	NULL
``	NULL
*Â°	NULL
we	NULL
have	NULL
found	NULL
no	NULL
evidence	NULL
for	NULL
chromosomal	NULL
aberrations	NULL
of	NULL
the	NULL
PU.1	NULL
loci	NULL
in	NULL
the	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

This	NULL
does	NULL
not	NULL
exclude	NULL
minor	NULL
alterations	NULL
such	NULL
as	NULL
small	NULL
deletions	NULL
or	NULL
point	NULL
mutations	NULL
.	NULL

(	NULL
2	NULL
)	NULL
An	NULL
alternative	NULL
interpretation	NULL
is	NULL
that	NULL
the	NULL
shutoff	NULL
of	NULL
the	NULL
PU.1	NULL
gene	NULL
is	NULL
a	NULL
normal	NULL
event	NULL
occurring	NULL
at	NULL
a	NULL
late	NULL
stage	NULL
of	NULL
B-cell	NULL
development	NULL
corresponding	NULL
to	NULL
that	NULL
of	NULL
the	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

This	NULL
interpretation	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
reduced	NULL
expression	NULL
and	NULL
activity	NULL
in	NULL
the	NULL
U-255	NULL
and	NULL
Corinna	NULL
II	NULL
cell	NULL
lines	NULL
representing	NULL
an	NULL
intermediate	NULL
stage	NULL
of	NULL
differentiation	NULL
.	NULL

Data	NULL
from	NULL
homozygous	NULL
gene-targeted	NULL
PU.1	NULL
mouse	NULL
embryos	NULL
suggest	NULL
that	NULL
PU.1	NULL
is	NULL
a	NULL
very	NULL
early	NULL
hematopoietic	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
generation	NULL
of	NULL
B-	NULL
and	NULL
T-lymphocyte	NULL
,	NULL
monocyte	NULL
,	NULL
and	NULL
granulocyte	NULL
progenitors	NULL
,	NULL
thus	NULL
acting	NULL
already	NULL
2751	NULL
at	NULL
a	NULL
stage	NULL
of	NULL
a	NULL
multipotent	NULL
stem	NULL
cell	NULL
.	NULL
``	NULL

This	NULL
interpretation	NULL
would	NULL
be	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
expression	NULL
studies	NULL
suggesting	NULL
that	NULL
PU.1	NULL
is	NULL
expressed	NULL
in	NULL
early	NULL
myeloid/lymphoid	NULL
cells	NULL
committed	NULL
to	NULL
the	NULL
erythroid	NULL
,	NULL
granulocytic	NULL
,	NULL
monocytic	NULL
,	NULL
mast	NULL
cell	NULL
,	NULL
B-	NULL
and	NULL
T-lymphoid	NULL
lineages	NULL
.	NULL

It	NULL
is	NULL
then	NULL
shut	NULL
off	NULL
early	NULL
in	NULL
T-cell	NULL
,	NULL
erythroid	NULL
,	NULL
and	NULL
granulocytic	NULL
differentiation	NULL
but	NULL
is	NULL
expressed	NULL
at	NULL
later	NULL
stages	NULL
of	NULL
monocytic	NULL
,	NULL
mast	NULL
cell	NULL
,	NULL
and	NULL
B-cell	NULL
differentiation	NULL
.	NULL

*	NULL
``	NULL
``	NULL
``	NULL
``	NULL
The	NULL
present	NULL
data	NULL
may	NULL
suggest	NULL
that	NULL
it	NULL
is	NULL
shut	NULL
off	NULL
late	NULL
during	NULL
B-cell	NULL
differentiation	NULL
,	NULL
thus	NULL
performing	NULL
its	NULL
function	NULL
at	NULL
preterminal	NULL
stages	NULL
of	NULL
B-cell	NULL
development	NULL
.	NULL

From	NULL
this	NULL
perspective	NULL
,	NULL
the	NULL
differences	NULL
in	NULL
expression	NULL
in	NULL
human	NULL
myelomas	NULL
and	NULL
murine	NULL
plasmacytomas	NULL
may	NULL
be	NULL
because	NULL
of	NULL
slight	NULL
differences	NULL
in	NULL
maturation	NULL
stage	NULL
or	NULL
a	NULL
malignancy-associated	NULL
inability	NULL
to	NULL
shut	NULL
off	NULL
PU.1	NULL
in	NULL
the	NULL
plasmacytomas	NULL
or	NULL
might	NULL
represent	NULL
a	NULL
species	NULL
difference	NULL
.	NULL

Studies	NULL
of	NULL
PU.1	NULL
expression	NULL
in	NULL
normal	NULL
human	NULL
and	NULL
mouse	NULL
plasma	NULL
cells	NULL
are	NULL
required	NULL
to	NULL
clarify	NULL
these	NULL
points	NULL
.	NULL

It	NULL
may	NULL
seem	NULL
remarkable	NULL
that	NULL
PU.1	NULL
is	NULL
shut	NULL
off	NULL
in	NULL
human	NULL
myeloma	NULL
cell	NULL
lines	NULL
that	NULL
produce	NULL
Ig	NULL
at	NULL
a	NULL
high	NULL
level	NULL
,	NULL
because	NULL
PU.1	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
one	NULL
important	NULL
transcriptional	NULL
activator	NULL
of	NULL
both	NULL
the	NULL
heavy-	NULL
and	NULL
light-chain	NULL
Ig	NULL
genes	NULL
.	NULL
``	NULL

However	NULL
,	NULL
there	NULL
are	NULL
alternative	NULL
pathways	NULL
of	NULL
Ig	NULL
gene	NULL
regulation	NULL
mediated	NULL
by	NULL
,	NULL
for	NULL
instance	NULL
,	NULL
Oct-2	NULL
and	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
acting	NULL
on	NULL
the	NULL
heavy	NULL
chain	NULL
enhancer	NULL
and	NULL
on	NULL
the	NULL
-chain	NULL
intron	NULL
enhancer	NULL
,	NULL
respectively	NULL
,	NULL
that	NULL
seem	NULL
to	NULL
increase	NULL
in	NULL
importance	NULL
at	NULL
late	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
.	NULL
``	NULL

Therefore	NULL
,	NULL
such	NULL
alternative	NULL
pathways	NULL
may	NULL
be	NULL
in	NULL
operation	NULL
in	NULL
the	NULL
human	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

Other	NULL
genes	NULL
suggested	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
PU.1	NULL
in	NULL
B	NULL
cells	NULL
are	NULL
the	NULL
J-chain	NULL
,	NULL
``	NULL
the	NULL
mb-1	NULL
and	NULL
B29	NULL
antigen	NULL
receptor-associated	NULL
signaling	NULL
proteins	NULL
,	NULL
``	NULL
3	NULL
;	NULL
integrins	NULL
,	NULL
``	NULL
and	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
antigens	NULL
.	NULL
``	NULL

The	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
seems	NULL
to	NULL
be	NULL
connected	NULL
to	NULL
B-cell	NULL
activation	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
IgM	NULL
secretion	NULL
at	NULL
preterminal	NULL
stages	NULL
of	NULL
differentiation	NULL
rather	NULL
than	NULL
to	NULL
terminally	NULL
differentiated	NULL
plasma	NULL
cells	NULL
or	NULL
myelomas	NULL
.	NULL

Therefore	NULL
,	NULL
one	NULL
interesting	NULL
possibility	NULL
is	NULL
that	NULL
PU.1	NULL
might	NULL
be	NULL
a	NULL
transcription	NULL
factor	NULL
which	NULL
integrates	NULL
differentiation	NULL
and	NULL
cell	NULL
growth	NULL
at	NULL
proliferative	NULL
stages	NULL
along	NULL
the	NULL
B-cell	NULL
differentiation	NULL
lineage	NULL
.	NULL

The	NULL
oncogenic	NULL
potential	NULL
of	NULL
PU.1/Spi-1	NULL
in	NULL
erythroleukemia	NULL
and	NULL
its	NULL
ability	NULL
to	NULL
interact	NULL
with	NULL
Rb	NULL
in	NULL
vitro	NULL
would	NULL
point	NULL
in	NULL
this	NULL
direction	NULL
.	NULL

Immunohistochemical	NULL
studies	NULL
in	NULL
normal	NULL
murine	NULL
bone	NULL
barrow	NULL
also	NULL
suggest	NULL
the	NULL
highest	NULL
expression	NULL
of	NULL
PU.1	NULL
in	NULL
dividing	NULL
cells	NULL
.	NULL
``	NULL

An	NULL
attractive	NULL
hypothesis	NULL
is	NULL
that	NULL
PU.1	NULL
is	NULL
replaced	NULL
by	NULL
an	NULL
alternative	NULL
Ets-family	NULL
or	NULL
a	NULL
non-Ets	NULL
transcription	NULL
factor	NULL
such	NULL
as	NULL
Oct-2	NULL
or	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
lacking	NULL
proliferative	NULL
or	NULL
having	NULL
an	NULL
antiproliferative	NULL
capacity	NULL
,	NULL
at	NULL
terminal	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
in	NULL
which	NULL
high	NULL
expression	NULL
of	NULL
the	NULL
differentiation-associated	NULL
genes	NULL
is	NULL
connected	NULL
to	NULL
irreversible	NULL
growth-arrest	NULL
.	NULL

Examples	NULL
of	NULL
other	NULL
Ets-family	NULL
members	NULL
expressed	NULL
in	NULL
hematopoietic	NULL
cells	NULL
are	NULL
Ets1	NULL
,	NULL
Ets2	NULL
,	NULL
Erg	NULL
,	NULL
Fli-1	NULL
,	NULL
Elf1	NULL
,	NULL
GABPa	NULL
,	NULL
and/or	NULL
SpiB	NULL
.	NULL
``	NULL

The	NULL
EMSA	NULL
and	NULL
transactivation	NULL
assays	NULL
in	NULL
the	NULL
myelomas	NULL
suggest	NULL
that	NULL
PU.1	NULL
is	NULL
not	NULL
replaced	NULL
by	NULL
an	NULL
Ets-family	NULL
protein	NULL
with	NULL
capacity	NULL
to	NULL
bind	NULL
the	NULL
SV40	NULL
Pu	NULL
box	NULL
.	NULL

However	NULL
,	NULL
other	NULL
PU.1	NULL
binding	NULL
sites	NULL
in	NULL
relevant	NULL
cellular	NULL
target	NULL
genes	NULL
may	NULL
have	NULL
a	NULL
broader	NULL
Ets-family	NULL
binding	NULL
specificity	NULL
that	NULL
could	NULL
result	NULL
in	NULL
a	NULL
competition	NULL
between	NULL
different	NULL
Ets-family	NULL
proteins	NULL
or	NULL
a	NULL
sequential	NULL
role	NULL
of	NULL
these	NULL
during	NULL
B-cell	NULL
development	NULL
.	NULL

Further	NULL
studies	NULL
of	NULL
PU.1	NULL
and	NULL
other	NULL
Ets-family	NULL
proteins	NULL
during	NULL
normal	NULL
B-cell	NULL
development	NULL
is	NULL
re	NULL
2752	NULL
quired	NULL
to	NULL
establish	NULL
whether	NULL
our	NULL
findings	NULL
in	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
represent	NULL
a	NULL
malignancy-associated	NULL
deregulation	NULL
of	NULL
PU.1	NULL
in	NULL
these	NULL
cells	NULL
or	NULL
exemplify	NULL
a	NULL
normal	NULL
phase	NULL
of	NULL
B-cell	NULL
differentiation	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
thank	NULL
Dr	NULL
L.	NULL
Hellman	NULL
for	NULL
providing	NULL
the	NULL
PU.1	NULL
cDNA	NULL
clone	NULL
,	NULL
Dr	NULL
C.	NULL
van	NULL
Beveren	NULL
for	NULL
providing	NULL
the	NULL
antiserum	NULL
against	NULL
the	NULL
N-terminal	NULL
part	NULL
of	NULL
PU.1	NULL
,	NULL
and	NULL
A.	NULL
Kraft	NULL
for	NULL
skillful	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Kerpler	NULL
I	NULL
,	NULL
Schaffner	NULL
W	NULL
:	NULL
Octamer	NULL
transcription	NULL
factors	NULL
and	NULL
the	NULL
cell	NULL
type-specificity	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
.	NULL

FASEB	NULL
J	NULL
4:1444	NULL
,	NULL
1990	NULL
2	NULL
.	NULL

Orkin	NULL
SH	NULL
:	NULL
GATA-binding	NULL
transcription	NULL
factors	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Blood	NULL
80:575	NULL
,	NULL
1992	NULL
3	NULL
.	NULL

Pettersson	NULL
M	NULL
,	NULL
Schaffner	NULL
W	NULL
:	NULL
A	NULL
purine-rich	NULL
DNA	NULL
sequence	NULL
motif	NULL
present	NULL
in	NULL
SV40	NULL
and	NULL
Lymphotropic	NULL
papovavirus	NULL
binds	NULL
a	NULL
lymphoid-specific	NULL
factor	NULL
and	NULL
contributes	NULL
to	NULL
enhancer	NULL
activity	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Genes	NULL
Dev	NULL
1:962	NULL
,	NULL
1987	NULL
4	NULL
.	NULL

Kiemsz	NULL
MJ	NULL
,	NULL
McKercher	NULL
SR	NULL
,	NULL
Celada	NULL
A	NULL
,	NULL
Van	NULL
Beveren	NULL
C	NULL
,	NULL
Maki	NULL
RA	NULL
:	NULL
The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
6:113	NULL
,	NULL
1990	NULL
5	NULL
.	NULL

Scott	NULL
EW	NULL
,	NULL
Simon	NULL
MC	NULL
,	NULL
Anastasi	NULL
J	NULL
,	NULL
Singh	NULL
H	NULL
:	NULL
Requirement	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
in	NULL
the	NULL
development	NULL
of	NULL
multiple	NULL
hematopoietic	NULL
lineages	NULL
.	NULL

Science	NULL
265:1573	NULL
,	NULL
1994	NULL
6	NULL
.	NULL

Karim	NULL
FD	NULL
,	NULL
Urness	NULL
LD	NULL
,	NULL
Thummel	NULL
CS	NULL
,	NULL
Klemsz	NULL
MJ	NULL
,	NULL
McKercher	NULL
SR	NULL
,	NULL
Celada	NULL
A	NULL
,	NULL
Van	NULL
Beveren	NULL
C	NULL
,	NULL
Maki	NULL
RA	NULL
,	NULL
Gunther	NULL
CV	NULL
,	NULL
Nye	NULL
JA	NULL
,	NULL
Graves	NULL
BJ	NULL
:	NULL
The	NULL
ETS-domain	NULL
:	NULL
A	NULL
new	NULL
DNA-binding	NULL
motif	NULL
that	NULL
recognizes	NULL
a	NULL
purine-rich	NULL
core	NULL
DNA	NULL
sequence	NULL
.	NULL

Genes	NULL
Dev	NULL
4:1451	NULL
,	NULL
1990	NULL
7	NULL
.	NULL

Wasylyk	NULL
B	NULL
,	NULL
Hahn	NULL
SL	NULL
,	NULL
Giovane	NULL
A	NULL
:	NULL
The	NULL
Ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Eur	NULL
J	NULL
Biochem	NULL
211:7	NULL
,	NULL
1993	NULL
8	NULL
.	NULL

Shin	NULL
MK	NULL
,	NULL
Koshland	NULL
ME	NULL
:	NULL
Ets-related	NULL
protein	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
immunoglobulin	NULL
J-chain	NULL
gene	NULL
through	NULL
a	NULL
novel	NULL
Ets-binding	NULL
element	NULL
.	NULL

Genes	NULL
Dev	NULL
7:2006	NULL
,	NULL
1993	NULL
9	NULL
.	NULL

Hagemeier	NULL
C	NULL
,	NULL
Bannister	NULL
AJ	NULL
,	NULL
Cook	NULL
A	NULL
,	NULL
Kouzarides	NULL
T	NULL
:	NULL
The	NULL
activation	NULL
domain	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
the	NULL
retinoblastoma	NULL
(	NULL
RB	NULL
)	NULL
protien	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
TFIID	NULL
in	NULL
vifro	NULL
:	NULL
RB	NULL
shows	NULL
sequence	NULL
similarity	NULL
to	NULL
TFIID	NULL
and	NULL
TFIIB	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:1580	NULL
,	NULL
1993	NULL
10	NULL
,	NULL
Pongubala	NULL
JMR	NULL
,	NULL
Van	NULL
Beveren	NULL
C	NULL
,	NULL
Nagulapalli	NULL
S	NULL
,	NULL
Klemsz	NULL
MJ	NULL
,	NULL
McKercher	NULL
SR	NULL
,	NULL
Maki	NULL
RA	NULL
,	NULL
Atchison	NULL
ML	NULL
:	NULL
Effect	NULL
of	NULL
PU.1	NULL
phosphory-lation	NULL
on	NULL
interaction	NULL
with	NULL
NF-EMS	NULL
and	NULL
transcriptional	NULL
activation	NULL
.	NULL

Science	NULL
259:1622	NULL
,	NULL
1993	NULL
11	NULL
.	NULL

Moreau-Gachelin	NULL
F	NULL
,	NULL
Tavitian	NULL
A	NULL
,	NULL
Tambourin	NULL
P	NULL
:	NULL
Spi-	NULL
!	NULL

is	NULL
a	NULL
putative	NULL
oncogene	NULL
in	NULL
virally	NULL
induced	NULL
murine	NULL
erythroleukaemias	NULL
.	NULL

Nature	NULL
331:277	NULL
,	NULL
1988	NULL
12	NULL
.	NULL

Schuetze	NULL
S	NULL
,	NULL
Stenberg	NULL
PE	NULL
,	NULL
Kabat	NULL
D	NULL
:	NULL
The	NULL
Ets-related	NULL
transcription	NULL
factor	NULL
PU.1	NULL
immortalizes	NULL
erythroblasts	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:5670	NULL
,	NULL
1993	NULL
13	NULL
.	NULL

Delgado	NULL
MD	NULL
,	NULL
Halliee	NULL
M	NULL
,	NULL
Meneceur	NULL
P	NULL
,	NULL
Tavitian	NULL
A	NULL
,	NULL
Moreau-Gachelin	NULL
F	NULL
:	NULL
Inhibition	NULL
of	NULL
Friend	NULL
cells	NULL
proliferation	NULL
by	NULL
spi-1	NULL
antisense	NULL
oligodeoxynucleotides	NULL
.	NULL

Oncogene	NULL
9:1723	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Ben-David	NULL
Y	NULL
,	NULL
Giddens	NULL
EB	NULL
,	NULL
Letwin	NULL
K	NULL
,	NULL
Bernstein	NULL
A	NULL
:	NULL
Erythroleukemia	NULL
induction	NULL
by	NULL
Friend	NULL
murine	NULL
leukemia	NULL
virus	NULL
:	NULL
Insertional	NULL
activation	NULL
of	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
ets	NULL
gene	NULL
family	NULL
,	NULL
Fli-1	NULL
,	NULL
closely	NULL
linked	NULL
to	NULL
c-ets-1	NULL
.	NULL

Genes	NULL
Dev	NULL
5:908	NULL
,	NULL
1991	NULL
15	NULL
.	NULL

Schuetze	NULL
S	NULL
,	NULL
Paul	NULL
R	NULL
,	NULL
Gliniak	NULL
BC	NULL
,	NULL
Kabat	NULL
D	NULL
:	NULL
Role	NULL
of	NULL
the	NULL
PU.1	NULL
transcription	NULL
factor	NULL
in	NULL
controlling	NULL
differentiation	NULL
of	NULL
Friend	NULL
erythroleukemia	NULL
cells	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
12:2967	NULL
,	NULL
1992	NULL
16	NULL
.	NULL

Galson	NULL
DL	NULL
,	NULL
Hensold	NULL
JO	NULL
,	NULL
Bishop	NULL
TR	NULL
,	NULL
Schalling	NULL
M	NULL
,	NULL
D'Andrea	NULL
AD	NULL
,	NULL
Jones	NULL
C	NULL
,	NULL
Auron	NULL
PE	NULL
,	NULL
Housman	NULL
DE	NULL
:	NULL
Mouse	NULL
DNA-binding	NULL
protien	NULL
B1	NULL
is	NULL
identical	NULL
to	NULL
a	NULL
proto-oncogene	NULL
,	NULL
the	NULL
transcription	NULL
PETTERSSON	NULL
ET	NULL
AL	NULL
factor	NULL
Spi-1/PU.1	NULL
,	NULL
and	NULL
is	NULL
restricted	NULL
in	NULL
expression	NULL
to	NULL
hematopoietic	NULL
cells	NULL
and	NULL
the	NULL
testis	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:2929	NULL
,	NULL
1993	NULL
17	NULL
.	NULL

Hromas	NULL
R	NULL
,	NULL
Orazi	NULL
A	NULL
,	NULL
Neiman	NULL
RS	NULL
,	NULL
Maki	NULL
R	NULL
,	NULL
Van	NULL
Beveren	NULL
C	NULL
,	NULL
Moore	NULL
J	NULL
,	NULL
Klemsz	NULL
M	NULL
:	NULL
Hematopoietic	NULL
lineage-	NULL
and	NULL
stage-restricted	NULL
expression	NULL
of	NULL
the	NULL
ETS	NULL
oncogene	NULL
family	NULL
member	NULL
PU.1	NULL
.	NULL

Blood	NULL
82:2998	NULL
,	NULL
1993	NULL
18	NULL
.	NULL

Hagman	NULL
J	NULL
,	NULL
Grosschedl	NULL
R	NULL
:	NULL
An	NULL
inhibitory	NULL
carboxyl-terminal	NULL
domain	NULL
in	NULL
Ets-1	NULL
and	NULL
Ets-2	NULL
mediates	NULL
differential	NULL
binding	NULL
of	NULL
ETS	NULL
family	NULL
factors	NULL
to	NULL
promoter	NULL
sequences	NULL
of	NULL
the	NULL
mb-1	NULL
gene	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:8889	NULL
,	NULL
1992	NULL
19	NULL
.	NULL

Nelsen	NULL
B	NULL
,	NULL
Tian	NULL
G	NULL
,	NULL
Erman	NULL
B	NULL
,	NULL
Gregoire	NULL
J	NULL
,	NULL
Maki	NULL
R	NULL
,	NULL
Graves	NULL
B	NULL
,	NULL
Sen	NULL
R	NULL
:	NULL
Regulation	NULL
of	NULL
lymphoid-specific	NULL
immunoglobulin	NULL
a	NULL
heavy	NULL
chain	NULL
gene	NULL
enhancer	NULL
by	NULL
ETS-domain	NULL
proteins	NULL
.	NULL

Science	NULL
261:82	NULL
,	NULL
1993	NULL
20	NULL
.	NULL

Omori	NULL
SA	NULL
,	NULL
Wall	NULL
R	NULL
:	NULL
Multiple	NULL
motifs	NULL
regulate	NULL
the	NULL
B-cell-specific	NULL
promoter	NULL
of	NULL
the	NULL
B29	NULL
gene	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:11723	NULL
,	NULL
1993	NULL
21	NULL
.	NULL

Pahl	NULL
HL	NULL
,	NULL
Scheibe	NULL
RJ	NULL
,	NULL
Zhang	NULL
D-E	NULL
,	NULL
Chen	NULL
H-M	NULL
,	NULL
Galson	NULL
DL	NULL
,	NULL
Maki	NULL
RA	NULL
,	NULL
Tenen	NULL
DG	NULL
:	NULL
The	NULL
proto-oncogene	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11b	NULL
promoter	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:5014	NULL
,	NULL
1993	NULL
22	NULL
.	NULL

Rivera	NULL
RR	NULL
,	NULL
Stuiver	NULL
MH	NULL
,	NULL
Steenbergen	NULL
R	NULL
,	NULL
Murre	NULL
C	NULL
:	NULL
Ets	NULL
proteins	NULL
:	NULL
New	NULL
factors	NULL
that	NULL
regulate	NULL
immunoglobulin	NULL
heavy-chain	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:7163	NULL
,	NULL
1993	NULL
23	NULL
.	NULL

Bottinger	NULL
EP	NULL
,	NULL
Shelley	NULL
CS	NULL
,	NULL
Farokhzad	NULL
OC	NULL
,	NULL
Arnaout	NULL
MA	NULL
:	NULL
The	NULL
human	NULL
32	NULL
integrin	NULL
CD18	NULL
promoter	NULL
consists	NULL
of	NULL
two	NULL
inverted	NULL
ets	NULL
cis	NULL
elements	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:2604	NULL
,	NULL
1994	NULL
24	NULL
.	NULL

Zhang	NULL
D-E	NULL
,	NULL
Hetherington	NULL
CJ	NULL
,	NULL
Chen	NULL
H-M	NULL
,	NULL
Tenen	NULL
DG	NULL
:	NULL
The	NULL
macrophage	NULL
transcription	NULL
factor	NULL
PU.1	NULL
directs	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14	NULL
;	NULL
:373	NULL
,	NULL
1994	NULL
25	NULL
.	NULL

Chen	NULL
H-M	NULL
,	NULL
Pahl	NULL
HL	NULL
,	NULL
Scheibe	NULL
RJ	NULL
,	NULL
Zhang	NULL
D-E	NULL
,	NULL
Tenen	NULL
DG	NULL
:	NULL
The	NULL
Sp1	NULL
transcription	NULL
factor	NULL
binds	NULL
the	NULL
CD11b	NULL
promoter	NULL
specifically	NULL
in	NULL
the	NULL
myeloid	NULL
cells	NULL
in	NULL
vivo	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
myeloid-specific	NULL
promoter	NULL
activity	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:8230	NULL
,	NULL
1993	NULL
26	NULL
.	NULL

Schneider	NULL
U	NULL
,	NULL
Schwenk	NULL
H-U	NULL
,	NULL
Bornkamm	NULL
G	NULL
:	NULL
Characterization	NULL
of	NULL
EBV-genome	NULL
negative	NULL
``	NULL
null	NULL
``	NULL
``	NULL
and	NULL
``	NULL
``	NULL
T	NULL
``	NULL
``	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
children	NULL
with	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
and	NULL
leukemic	NULL
transformed	NULL
non-Hodgkin	NULL
lymphoma	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
19:621	NULL
,	NULL
1977	NULL
27	NULL
.	NULL

Nilsson	NULL
K	NULL
,	NULL
Klein	NULL
G	NULL
:	NULL
Phenotypic	NULL
and	NULL
cytogenetic	NULL
characteristics	NULL
of	NULL
human	NULL
B-lymphoid	NULL
cell	NULL
lines	NULL
and	NULL
their	NULL
relevance	NULL
for	NULL
the	NULL
etiology	NULL
of	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
.	NULL

Adv	NULL
Cancer	NULL
Res	NULL
37:319	NULL
,	NULL
1982	NULL
28	NULL
.	NULL

Dyer	NULL
MJS	NULL
,	NULL
Fischer	NULL
P	NULL
,	NULL
Nacheva	NULL
E	NULL
,	NULL
Labastide	NULL
W	NULL
,	NULL
Karpas	NULL
A	NULL
:	NULL
A	NULL
new	NULL
human	NULL
B-cell	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
(	NULL
Karpas	NULL
422	NULL
)	NULL
exhibiting	NULL
both	NULL
t	NULL
(	NULL
14	NULL
;	NULL
18	NULL
)	NULL
and	NULL
t	NULL
(	NULL
4	NULL
;	NULL
11	NULL
)	NULL
chromosomal	NULL
translocations	NULL
.	NULL

Blood	NULL
75:709	NULL
,	NULL
1990	NULL
29	NULL
.	NULL

Nilsson	NULL
K	NULL
:	NULL
Characteristics	NULL
of	NULL
established	NULL
myeloma	NULL
and	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
an	NULL
E	NULL
myeloma	NULL
patient	NULL
:	NULL
A	NULL
comparative	NULL
study	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
7:380	NULL
,	NULL
1971	NULL
30	NULL
.	NULL

Karpas	NULL
A	NULL
,	NULL
Fischer	NULL
P	NULL
,	NULL
Swirsky	NULL
D	NULL
:	NULL
Human	NULL
myeloma	NULL
cell	NULL
line	NULL
carrying	NULL
a	NULL
Philadelphia	NULL
chromosome	NULL
.	NULL

Science	NULL
216:997	NULL
,	NULL
1982	NULL
31	NULL
.	NULL

Diehl	NULL
V	NULL
,	NULL
Schaadt	NULL
M	NULL
,	NULL
Kirchner	NULL
H	NULL
,	NULL
Hellriegel	NULL
K-P	NULL
,	NULL
Gudat	NULL
F	NULL
,	NULL
Fonatsch	NULL
C	NULL
,	NULL
Laskewitz	NULL
E	NULL
,	NULL
Guggenheim	NULL
R	NULL
:	NULL
Long-term	NULL
cultivation	NULL
of	NULL
plasma	NULL
cell	NULL
leukemia	NULL
cells	NULL
and	NULL
autologous	NULL
lymphoblasts	NULL
(	NULL
LCL	NULL
)	NULL
in	NULL
vitro	NULL
:	NULL
A	NULL
comparative	NULL
study	NULL
.	NULL

Blut	NULL
36:331	NULL
,	NULL
1978	NULL
32	NULL
.	NULL

Jernberg	NULL
H	NULL
,	NULL
Nilsson	NULL
K	NULL
,	NULL
Zech	NULL
L	NULL
,	NULL
Lutz	NULL
D	NULL
,	NULL
Nowotny	NULL
H	NULL
,	NULL
Scheirer	NULL
W	NULL
:	NULL
Establishment	NULL
and	NULL
phenotypic	NULL
charaterization	NULL
of	NULL
three	NULL
new	NULL
human	NULL
myeloma	NULL
cell	NULL
lines	NULL
(	NULL
U-1957	NULL
,	NULL
U-1958	NULL
,	NULL
and	NULL
U-1996	NULL
)	NULL
.	NULL

Blood	NULL
69:1605	NULL
,	NULL
1987	NULL
33	NULL
.	NULL

Hellman	NULL
L	NULL
,	NULL
Josephson	NULL
S	NULL
,	NULL
Jernberg	NULL
H	NULL
,	NULL
Nilsson	NULL
K	NULL
,	NULL
Pettersson	NULL
U	NULL
:	NULL
Immunoglobulin	NULL
synthesis	NULL
in	NULL
the	NULL
human	NULL
myeloma	NULL
cell	NULL
line	NULL
U-266	NULL
;	NULL
expression	NULL
of	NULL
two	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
isotypes	NULL
(	NULL
e	NULL
and	NULL
a	NULL
)	NULL
after	NULL
long-term	NULL
cultivation	NULL
in	NULL
vitro	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
18:905	NULL
,	NULL
1988	NULL
34	NULL
.	NULL

Luthman	NULL
H	NULL
,	NULL
Magnusson	NULL
G	NULL
:	NULL
High	NULL
efficiency	NULL
polyoma	NULL
DNA	NULL
transfection	NULL
of	NULL
chloroquine	NULL
treated	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
11:1295	NULL
,	NULL
1983	NULL
PU.1	NULL
EXPRESSION	NULL
IN	NULL
HUMAN	NULL
B	NULL
CELLS	NULL
35	NULL
.	NULL

Gorman	NULL
CM	NULL
,	NULL
Moffat	NULL
LF	NULL
,	NULL
Howard	NULL
BH	NULL
:	NULL
Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
Cell	NULL
Biot	NULL
2:1044	NULL
,	NULL
1982	NULL
36	NULL
.	NULL

Zervitz	NULL
K	NULL
,	NULL
Akusjirvi	NULL
G	NULL
:	NULL
An	NULL
improved	NULL
nuclear	NULL
extract	NULL
preparation	NULL
method	NULL
.	NULL

Gene	NULL
Anal	NULL
Tech	NULL
6:101	NULL
,	NULL
1989	NULL
37	NULL
.	NULL

Westin	NULL
G	NULL
,	NULL
Gerster	NULL
T	NULL
,	NULL
Miiller	NULL
MM	NULL
,	NULL
Schaffner	NULL
G	NULL
,	NULL
Schaffner	NULL
W	NULL
:	NULL
OVEC	NULL
,	NULL
a	NULL
versatile	NULL
system	NULL
to	NULL
study	NULL
transcription	NULL
in	NULL
mammalian	NULL
cells	NULL
and	NULL
cell-free	NULL
extracts	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
15:6787	NULL
,	NULL
1987	NULL
38	NULL
.	NULL

Auffray	NULL
C	NULL
,	NULL
Rougeon	NULL
F	NULL
:	NULL
Purification	NULL
of	NULL
total	NULL
mouse	NULL
immunoglobulin	NULL
heavy-chain	NULL
messenger	NULL
RNAs	NULL
from	NULL
total	NULL
myeloma	NULL
tumor	NULL
RNA	NULL
.	NULL

Eur	NULL
J	NULL
Biochem	NULL
107:303	NULL
,	NULL
1980	NULL
39	NULL
.	NULL

Tso	NULL
JY	NULL
,	NULL
Sun	NULL
X-H	NULL
,	NULL
Kao	NULL
T	NULL
,	NULL
Reece	NULL
KS	NULL
,	NULL
Wu	NULL
R	NULL
:	NULL
Isolation	NULL
and	NULL
characterization	NULL
of	NULL
rat	NULL
and	NULL
human	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
cDNAs	NULL
:	NULL
Genomic	NULL
complexity	NULL
and	NULL
molecular	NULL
evolution	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
13:2485	NULL
,	NULL
1985	NULL
40	NULL
.	NULL

Reddy	NULL
ESP	NULL
,	NULL
Rao	NULL
VN	NULL
:	NULL
erg	NULL
,	NULL
An	NULL
ets-related	NULL
gene	NULL
,	NULL
codes	NULL
for	NULL
sequence-specific	NULL
transcriptional	NULL
activators	NULL
.	NULL

Oncogene	NULL
6:2285	NULL
,	NULL
1991	NULL
41	NULL
.	NULL

Rao	NULL
VN	NULL
,	NULL
Reddy	NULL
ESP	NULL
:	NULL
A	NULL
divergent	NULL
ets-related	NULL
protein	NULL
,	NULL
Elk-1	NULL
,	NULL
2753	NULL
recognizes	NULL
similar	NULL
c-ets-1	NULL
proto-oncogene	NULL
target	NULL
sequences	NULL
and	NULL
acts	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
.	NULL

Oncogene	NULL
7:65	NULL
,	NULL
1992	NULL
42	NULL
.	NULL

Rao	NULL
VN	NULL
,	NULL
Ohno	NULL
T	NULL
,	NULL
Prasad	NULL
DDK	NULL
,	NULL
Bhattacharya	NULL
G	NULL
,	NULL
Reddy	NULL
ESP	NULL
:	NULL
Analysis	NULL
of	NULL
the	NULL
DNA-binding	NULL
and	NULL
transcriptional	NULL
activation	NULL
functions	NULL
of	NULL
human	NULL
Fli-1	NULL
protein	NULL
.	NULL

Oncogene	NULL
8:2167	NULL
,	NULL
1993	NULL
43	NULL
.	NULL

Wasylyk	NULL
C	NULL
,	NULL
Kerckaert	NULL
J-P	NULL
,	NULL
Wasylyk	NULL
B	NULL
:	NULL
A	NULL
novel	NULL
modulator	NULL
domain	NULL
of	NULL
Ets	NULL
transcription	NULL
factors	NULL
.	NULL

Genes	NULL
Dev	NULL
6:965	NULL
,	NULL
1992	NULL
44	NULL
.	NULL

Rogers	NULL
S	NULL
,	NULL
Wells	NULL
R	NULL
,	NULL
Rechsteiner	NULL
M	NULL
:	NULL
Amino	NULL
acid	NULL
sequences	NULL
common	NULL
to	NULL
rapidly	NULL
degraded	NULL
proteins	NULL
:	NULL
The	NULL
PEST	NULL
hypothesis	NULL
.	NULL

Science	NULL
234	NULL
;	NULL
364	NULL
,	NULL
1986	NULL
45	NULL
.	NULL

Pongubala	NULL
JMR	NULL
,	NULL
Atchison	NULL
ML	NULL
:	NULL
Functional	NULL
characterization	NULL
of	NULL
the	NULL
developmentally	NULL
controlled	NULL
immunoglobulin	NULL
kappa	NULL
3	NULL
'	NULL
enhancer	NULL
:	NULL
Regulation	NULL
by	NULL
Id	NULL
,	NULL
a	NULL
repressor	NULL
of	NULL
helix-loop-helix	NULL
transcription	NULL
factors	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
11:1040	NULL
,	NULL
1991	NULL
46	NULL
.	NULL

Jernberg	NULL
H	NULL
,	NULL
Zech	NULL
L	NULL
,	NULL
Nilsson	NULL
K	NULL
:	NULL
Cytogenetic	NULL
studies	NULL
on	NULL
human	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
40:811	NULL
,	NULL
1987	NULL
47	NULL
.	NULL

Corcoran	NULL
LM	NULL
,	NULL
Karvelas	NULL
M	NULL
,	NULL
Nossal	NULL
GJV	NULL
,	NULL
Ye	NULL
Z-8	NULL
,	NULL
Jacks	NULL
T	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Oct-2	NULL
,	NULL
although	NULL
not	NULL
required	NULL
for	NULL
early	NULL
B-cell	NULL
development	NULL
,	NULL
is	NULL
critical	NULL
for	NULL
later	NULL
B-cell	NULL
maturation	NULL
and	NULL
for	NULL
postnatal	NULL
survival	NULL
.	NULL

Genes	NULL
Dev	NULL
7:570	NULL
,	NULL
1993	NULL

